1. Generics Bulletin
  2. >>Business

Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab

Strikes Deal In Multiple Global Markets For SB17 Biosimilar Rival To Stelara

 
• By Dave Wallace

Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.

Hand placing jigsaw puzzle piece into gap
Another piece of Sandoz’s biosimilars portfolio has fallen into place • Source: Shutterstock

Just days ahead of a meeting that will see shareholders vote on its upcoming separation from parent company Novartis, Sandoz has struck a deal with Samsung Bioepis for rights to the Korean firm’s SB17 proposed biosimilar to Stelara (ustekinumab) in the US, Canada, EEA, Switzerland, and UK.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.